Cell therapy (Stem-cell derived) · Immune activation · developed by Celularity
PDA001 is a human placenta-derived cell therapy administered intravenously. It is studied in rheumatoid arthritis, Crohn's disease, acute stroke, and pulmonary sarcoidosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01310114 | Phase 2 | Stroke, Acute | Terminated | CELU |
| NCT01261403 | Phase 2 | Rheumatoid Arthritis | Terminated | CELU |
| NCT01155362 | Phase 2 | Crohn's Disease | Completed | CELU |
| NCT01440192 | Phase 1 | Stage 2 Pulmonary Sarcoidosis | Terminated | CELU |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Crohn's DiseaseMiddle Cerebral Artery StrokePosterior Cerebral Artery StrokeRheumatoid ArthritisStage 2 Pulmonary SarcoidosisStage 3 Pulmonary SarcoidosisStroke, Acute
Updated Oct 3, 2026. Something wrong or missing? Report it on the CELU page.
See CELU's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CELU catalysts and pipeline →